Changes for page Pieris Pharmaceuticals

Last modified by Asif Farooqui on 2019/12/09 16:57
From version < 1.3 >
edited by Asif Farooqui
on 2019/12/09 16:55
To version < 1.4 >
edited by Asif Farooqui
on 2019/12/09 16:57
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,9 +2,9 @@
2 2  {{toc/}}
3 3  {{/box}}
4 4  
5 -= Paragraph 1 =
5 += =
6 6  
7 -Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
7 +Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.{{footnote}}https://fintel.io/doc/sec-pirs-pieris-pharmaceuticals-10k-2018-march-15-17944{{/footnote}}
8 8  
9 9  Each of its development programs focus on the following:
10 10  
... ... @@ -35,4 +35,6 @@
35 35  
36 36  A significant portion of Pieris' operations are conducted in countries other than the United States. Since Pieris conduct its business in U.S. dollars, its main exposure, if any, results from changes in the exchange rates between the euro and the U.S. dollar. All assets and liabilities denominated in euros are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average rate during the period. Equity transactions are translated using historical exchange rates. Adjustments resulting from translating foreign currency financial statements into U.S. dollars are included in accumulated other comprehensive loss. Pieris may incur negative foreign currency translation changes as a result of changes in currency exchange rates.
37 37  
38 -
38 += References =
39 +
40 +{{putFootnotes/}}
This site is funded and maintained by Fintel.io